Disclosed are conjugated polymer nanoparticles and a method of producing the same. The conjugated polymer nanoparticles include a conjugated polymer, fatty acid and an amphiphile polymer. The conjugated polymer nanoparticles can be doped even under a neutral environment, thus exhibiting high electrical conductivity and exerting absorbance properties in the near-infrared band even under a neutral environment such as in vivo.

A principle is established to show that nanoscale energy deposition in water by X-rays can be greatly enhanced via the geometry of nanostructures. The calculated results show that enhancement over background water can reach over 60 times for a single nanoshell made of gold. Other geometries and nanostructures are investigated, and it is found that a shell of gold nanoparticles can generate similar enhancement. The concepts of composition, matrix, and satellite effects are established and studied, all of which can further increase the enhancement of the effect of X-rays.

Disclosed herein is a method for treating a cancer, the method includes following operations. A pharmaceutical composition is administered to a subject in need. The pharmaceutical composition includes a medium and a plurality of cisplatin-loaded microbubbles dispersed in the medium. Each cisplatin-loaded microbubble includes a shell portion and a core portion. The shell portion includes a plurality of albumin molecules and a plurality of first cisplatin molecules covalently bonding to the albumin molecules. The core portion is surrounded by the shell portion, wherein the core portion includes a mixture of inert gas and a plurality of second cisplatin molecules. Ultrasound energy is then applied to a tumor of the subject to break the cisplatin-loaded microbubbles.

The present invention relates to a method for transiently disrupting a region of the blood-brain barrier (BBB) of a human using ultrasounds in the presence of an ultrasound contrast agent, and uses thereof. The method comprises the application of at least one ultrasound (US) beam with a pressure level higher than 1 MPa and a resonance frequency ranging from 0.5 to 1.5 MHz.

A method for increasing the release of at least one compound, the compound being initially an initial compound bound to at least one initial nanoparticle, the initial compound bound to the initial nanoparticle forming an initial particle, wherein the initial particle includes at least one active ingredient, the method including at least one step of alteration of the initial particle and at least one step of physico-chemical disturbance of an altered particle resulting from the alteration.

Provided herein are compositions, systems, kits, and methods for administering a gel composition into a tumor of a subject and treating with laser light (e.g., for photoacoustic destruction of the tumor and tumor debris generation), where the gel comprises functionalized fullerenes (FFs) and a biocompatible polymer. In certain embodiments, 0.1-5% (e.g., about 1-2%) by weight of the gel is the functionalized fullerenes (e.g., polyhydroxy fullerenes). In other embodiments, the FFs have a generally symmetrical spherical structure.

An ultrasound system for use in unbinding an active agent from a plasma protein in a target site in a subject includes a transducer configured to generate acoustic pressure waves and a controller coupled to the transducer. The controller is programmed to control the transducer to produce a plurality of pulsed acoustic pressure waves in the target site of the patient. The plurality of pulsed acoustic pressure waves disrupt a plasma protein binding between the active agent and the plasma protein within the target site. The disruption of the plasma protein binding causes an increase in an amount of unbound active agent in the target site.

The present document describes methods of using compositions for inhibiting biofilm formation, or disrupting existing or developing biofilms in a subject, which composition comprises at least one chromophore and a pharmacologically acceptable carrier.

The present invention provides for thermosensitive hydrogel for cancer therapeutic and methods of preparation thereof. The invention represents an advancement in the field of cancer therapeutics and provides for a polymer-protein based thermosensitive hydrogel comprising polyvinyl alcohol, poloxamer 407 and bovine serum albumin. The thermosensitive hydrogel can be optionally be enriched with one or more additional component such as photothermal agents, photosensitizers, drugs and dyes. The invention also provides for a method of preparing the thermosensitive hydrogels. The hydrogels of the present invention are inexpensive, thermosensitive, has ability to effectuate sustained release of drugs and can be used for targeted delivery and dual-modality treatment.

Methods for the treatment of stroke, such as stroke of undetermined origin, by administration of xenon (Xe)-loaded liposome compositions are provided. In some aspects, Xe is encapsulated in echogenic liposomes and release of Xe can be enhanced by application of ultrasound stimulation. Compositions for use in treating stroke, such as liposomes loaded with Xe or Xe in combination with H2 or H2S, are also provided.